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inﬂammatory drug (NSAID) (meloxicam). For each cohort, use
of prescription analgesics was tracked pre-withdrawal (January-
September 2004) and post-withdrawal (2005–2006). The impact
of the withdrawal on drug utilization by former rofecoxib users
was assessed by comparing changes in their drug consumption
with that of celecoxib or meloxicam users during the same time
period. RESULTS: The study cohorts included: 29,438 rofe-
coxib, 34,937 celecoxib, and 7131 meloxicam users. The groups
were demographically similar, except for a higher proportion of
women in the meloxicam cohort. In 2005, former rofecoxib users
primarily substituted other COX-2 inhibitors (22% celecoxib,
10% valdecoxib) or non-selective NSAIDS (which increased to
48% from 14% pre-withdrawal). There was no substantial
change in use of opioid /other analgesics. The percentage of
former rofecoxib users continuing to receive any prescription
analgesic was 83% (2005) and 77% (2006). By comparison,
overall utilization of celecoxib and meloxicam declined to 87%
and 91% respectively in 2005 and 80% and 84% respectively in
2006. By 2006, 59% of celecoxib users and 53% of meloxicam
users had discontinued these medications. CONCLUSION: By
2006, the proportion of former rofecoxib users who had discon-
tinued prescription analgesics altogether was substantially higher
than among patients who not previously receiving a COX-2
inhibitor. This suggests the potential harm from unsafe drugs
may not be limited to side effects, but also includes the disruption
of care due to withdrawal of effective treatment.
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OBJECTIVE: Abatacept is a new biological DMARD with selec-
tive co-stimulation modulator mechanism of action that was
recently approved in Brazil for the treatment of patients with
moderate to severe RA. We aim to evaluate and describe the
budget impact of the inclusion of abatacept in the National
Program of Exceptional Medications (NPEM) with the tumor
necrosis factor (TNF) antagonists currently in use and included.
METHODS: Using data provided by Brazilian Ministry of
Health, our study estimates the cost associated with the inclusion
of Abatacept for inadequate responders to methotrexate and
TNF antagonists compared with actual scenario (without Abata-
cept). Our model presumes: adequate doses and regimen of
abatacept (10 mg/kg. 0, 2, 4, and each 4 weeks), inﬂiximab
(4.2 mg/kg each dose of inﬂiximab, 0, 2, 6, and each 8 weeks),
etanercept (25 mg each dose/twice a week) and adalimumab
(40 mg each dose, twice a month), and we accept the actual
distribution of TNF antagonists used by NPEM (with adoption
of 20% of increase in the number of the RA patients each
year—NPEM data). According to literature, 30% of the patients
with inadequate response to methotrexate will be eligible to use
abatacept, and we accept this percentage to introduce patients in
the abatacept group. The initial population is 4978 patients
currently in use of TNF antagonists in 2007. RESULTS: In the
ﬁrst year of inclusion there is an increase in costs of R$3,085,711
(US$1,763,263). In the second and third years there are signiﬁ-
cant savings on budgets, R$97,593,971 (US$55,767,983) and
R$129,458,357 (US$73,976,204), respectively. CONCLUSION:
The incorporation of abatacept into the NPEM is cost-saving to
the Brazilian Public Health System, saving R$129,458,357.00
(US$73,976,204) after the third year.
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OBJECTIVE: To conduct a cost-beneﬁt analysis to compare the
hypothetical introduction of a new intervention, internal ﬁxation
(IF), with hemiarthroplasty (HA) for the treatment of displaced
femoral neck fractures in patients greater than 60 years old.
METHODS: We estimated the costs from a third party payer
perspective after one year of two strategies (HA and IF) for the
treatment of femoral neck fractures in patients over the age of 60.
Using a decision board, we elicited patient preferences for the
two operative approaches and calculated the net beneﬁt using the
willingness-to-pay technique. RESULTS: The 1-year projected
cost of one IF was $18,100 and that of one HA was $15,843
(incremental cost of $2,257 for each IF). Of 108 participants, 61
(56.5%) chose IF as the preferred treatment option and were
willing to pay an average of $3.33 per month to have this option
available if needed. In Ontario, the total incremental cost of
performing IF in patients that choose it was $64,714,103, and
the total societal beneﬁt was $289,263,600, yielding a net beneﬁt
of $224,549,497. CONCLUSION: The beneﬁts of IF over HA
outweigh the incremental costs from the perspective of a third
party payer. Therefore, IF should be available to patients that
choose it.
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OBJECTIVE: Total hip arthroplasty (THA) is a common and
successful procedure with nearly 250,000 primary arthroplasties
performed yearly in the United States. This number is estimated
to increase by at least 5% annually over the next decade. The
resulting growth in health care utilization and costs maybe offset
by innovative implant technologies with increased survivorship.
This study quantiﬁes the economic cost savings to payers
from improved survivorship. METHODS: A simulation model
is developed to estimate the long-term cost implications of
improvements in THA survivorship. The model considers costs
associated with all primary hip replacements performed in the
United States over a ten-year horizon. The analysis draws upon
the literature to obtain information on long-term revision rates
for hip replacement surgeries. Inpatient treatment costs associ-
ated with THA and incidence and costs of the major complica-
tions, deep vein thrombosis and infection are included in the
model. RESULTS: Improved implant survivorship in THA is
estimated to save $1.6 billion over a ten-year horizon. The ma-
jority of these savings accrues from lower revision rates ($1.3
billion) with fewer complications accounting for $300 million in
additional savings. Sensitivity analyses reveal that cost savings
varied by survivorship ($1.1 to $2.0 billion) and hospital cost for
revision surgery ($1.3 to $3.1 billion). Other variations by phy-
sician costs, complications costs and discount rates are less pro-
nounced. However, under every scenario, costs savings are in
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